Literature DB >> 3909937

Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy.

D E Griffin, H W Moser, Q Mendoza, T R Moench, S O'Toole, A B Moser.   

Abstract

Adrenoleukodystrophy is a disorder of long-chain fatty acid metabolism associated with adrenal cortical insufficiency and central nervous system demyelination. The central nervous system disease is unusual in that it is abrupt in onset and accompanied by a considerable infiltration of mononuclear inflammatory cells. To determine the nature of these inflammatory cells, immunocytochemical staining was carried out on the mononuclear cells in the brain and cerebrospinal fluid of patients with adrenoleukodystrophy. Monoclonal antibodies to T lymphocytes (T11), the helper/inducer (T4) and cytotoxic/suppressor (T8) subsets of T lymphocytes, B lymphocytes (B1), and monocyte/macrophages (M1 or esterase) were used. Mononuclear cells in the perivascular cuffs of autopsy material from 4 patients were, on average, 59% T cells, 34% T4 cells, 16% T8 cells, 24% B cells, and 11% monocyte/macrophages. Cerebrospinal fluid from 8 of 10 patients had increased IgG concentrations. Mononuclear cells in the cerebrospinal fluid of 6 patients with active disease were, on average, 61% T cells, 40% T4 cells, 16% T8 cells, 3% B cells, and 18% monocyte/macrophages. This distribution of cells is similar to that found in the central nervous system during a cellular immune response and suggests the possibility that one component of this disease is immunologically mediated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3909937     DOI: 10.1002/ana.410180606

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  20 in total

1.  X-linked adrenoleukodystrophy: first report of the Italian Study Group.

Authors:  A Di Biase; S Salvati; C Avellino; M Cappa; E Bertini; I Moroni; M Rimoldi; G Uziel
Journal:  Ital J Neurol Sci       Date:  1998-10

Review 2.  X linked adrenoleukodystrophy: clinical presentation, diagnosis, and therapy.

Authors:  B M van Geel; J Assies; R J Wanders; P G Barth
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

3.  A mouse model for X-linked adrenoleukodystrophy.

Authors:  J F Lu; A M Lawler; P A Watkins; J M Powers; A B Moser; H W Moser; K D Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  Effects of exogenous hexacosanoic acid on biochemical myelin composition in weaning and post-weaning rats.

Authors:  A Di Biase; C Avellino; F Pieroni; T Quaresima; A Grisolia; M Cappa; S Salvati
Journal:  Neurochem Res       Date:  1997-03       Impact factor: 3.996

Review 5.  Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis.

Authors:  Inderjit Singh; Aurora Pujol
Journal:  Brain Pathol       Date:  2010-07       Impact factor: 6.508

6.  A new therapeutic approach for X-linked adrenoleukodystrophy.

Authors:  M Cappa; E Bertini; M Di Capua; M Rimoldi; G Uziel
Journal:  Eur J Pediatr       Date:  1990-05       Impact factor: 3.183

7.  Phenotypes of mononuclear cell infiltrates in human central nervous system.

Authors:  Y Iwasaki; K Sako; I Tsunoda; Y Ohara
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

8.  T-cell infiltration and expression of MHC class II antigen by macrophages and microglia in a heterogeneous group in leukoencephalopathy.

Authors:  H Tomimoto; I Akiguchi; H Akiyama; J Kimura; T Yanagihara
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

Review 9.  Adrenoleukodystrophy: biochemical procedures in diagnosis, prevention and treatment.

Authors:  P A Watkins; S Naidu; H W Moser
Journal:  J Inherit Metab Dis       Date:  1987       Impact factor: 4.982

Review 10.  Adrenoleukodystrophy: phenotypic variability and implications for therapy.

Authors:  H W Moser; A B Moser; K D Smith; A Bergin; J Borel; J Shankroff; O C Stine; C Merette; J Ott; W Krivit
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.